Comparative Pharmacology
Head-to-head clinical analysis: AYGESTIN versus NORETHINDRONE AND ETHINYL ESTRADIOL 7 14.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AYGESTIN versus NORETHINDRONE AND ETHINYL ESTRADIOL 7 14.
AYGESTIN vs NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial changes by binding to progesterone receptors.
Norethindrone is a progestin that suppresses gonadotropin release, preventing ovulation. Ethinyl estradiol is an estrogen that provides negative feedback on the hypothalamic-pituitary axis, further inhibiting ovulation. The combination also alters cervical mucus and endometrial lining to impede fertilization and implantation.
5 mg orally once daily for secondary amenorrhea; 5 mg orally once daily from day 5 to day 25 of menstrual cycle for abnormal uterine bleeding.
One tablet (norethindrone 0.5 mg/ethinyl estradiol 35 mcg) orally once daily for 21 days (7 active tablets of norethindrone 0.5 mg/ethinyl estradiol 35 mcg followed by 14 active tablets of norethindrone 1 mg/ethinyl estradiol 35 mcg). Start on day 1 of menstrual cycle.
None Documented
None Documented
Terminal half-life 5-12 hours; clinical context: requires twice-daily dosing for consistent serum levels.
Norethindrone: 8-11 hours; Ethinyl estradiol: 17-27 hours. Achieves steady state within 5-10 days, permitting once-daily dosing.
Approximately 50-80% renal as metabolites, 10-20% fecal; less than 1% unchanged.
Norethindrone: ~50% renal, ~50% fecal; Ethinyl estradiol: ~50% renal, ~50% fecal, with enterohepatic circulation.
Category C
Category D/X
Progestin
Progestin